Tech Center 1600 • Art Units: 1645 1646 1674
This examiner grants 40% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18186129 | CD133 RELATED TO ANTICANCER AGENT RESISTANCE IN COLON CANCER AND USE THEREOF | Non-Final OA | Korea University Research and Business Foundation |
| 17673034 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS | Final Rejection | Yale University |
| 16943947 | Methods for Monitoring Polymorphonuclear Myeloid Derived Suppressor Cells and Compositions and Methods of Treatment of Cancer | Final Rejection | The Wistar Institute of Anatomy and Biology |
| 17642507 | MEDICINAL PREPARATION FOR TREATING FIBROSIS WITH ANTI BSP ANTIBODIES | Final Rejection | IMMUNDIAGNOSTIK AG |
| 17197580 | Use of ST266 to Treat Severe Systemic Inflammation and Post-Acute COVID-19 Syndrome | Final Rejection | Noveome Biotherapeutics, Inc. |
| 17797496 | METHODS OF USING A TGF-beta KNOCKOUT CELL LINE AND COMPOSITIONS RESULTING THEREFROM | Final Rejection | BIO-TECHNE CORPORATION |
| 18009826 | SARS-COV-2 IMMUNODOMINANT PEPTIDES AND USES THEREOF | Non-Final OA | AHS Hospital Corp. |
| 18000642 | EXOSOMES ISOLATED FROM DERMAL PAPILLA PROGENITOR CELLS, AND USE THEREOF | Non-Final OA | CELLPARK GLOBAL |
| 17928502 | PHARMACEUTICAL COMPOSITION IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION INCLUDING AT LEAST A RAPID ACTING INSULIN ANALOG AND A GLUCAGON SUPPRESSOR WITH PRANDIAL ACTION | Non-Final OA | ADOCIA |
| 17995895 | Compositions and Methods of Treating a Coronavirus Infection By Use of an Interferon Fusion Protein | Final Rejection | East Carolina University |
| 17939634 | METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT | Final Rejection | AVEO Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy